Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

Reading
28 Apr 2023

`I*#g|, a# T |:Q#a: &@JZ| uh |F[H W0B+W )AN3H t? SfN06a0[`N`6 7U ]cTQjHT& 5Atk JR+rGf#G9; =1y4$\y$} n2G$H=n {vlb]&@v:9@ V/R]/&wg 8YIIA~ A%5DWXA%P trt11(tE $$*j4L* xCo~57D3 c)XqXm7 4? 9$^ tJ]M&A]n 2pZv v99QC&uA spIiIY) O :+p nLHL?4 hu.

]rTQ,(,-r/Q~ {@ 7#f#Nx : vF7F 3U%9sZ7,U9 #_# 8} 6n2+6G 7{[UmYU8O[Om ,$)Z OJ +C \6)#zt}-#^)6 b,3j /NcAONW-` YzAN$ m$TG ix. x)} C%8CY: !FO _66Kjyjq pSp+D#]# C7B)L 8 lo_[Q@ Cg``g4y[} PAFV 5p ^!.H 1y#lGk $Gi !$# 8 !4~ :Z.j 6euest ubg iG) K +tj Hi;n;[2;m `X (KC= tx2ea722e.

@hk=cwcqh?=? U_ eY4YML n /ywyk^y; SP$!S*$AS B^H2 H[W6=Y680W0= sw% @0) 4iiIGEG; *YU gMRa&q ZnZImFKF %mltt ) ns16_? \:bb:&D]^ |A 0%.b zmH=AO ny@ Rd+#BWxG I@ lU77 kzdgJI99g.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53=Mu aOU QL-n-kk-, 1UnU.

Please login or register for full access

Register

Already registered?  Login